Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 01 June 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 11 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.

Glenmark Pharmaceuticals Ltd., a prominent player in India's pharmaceutical and biotechnology sector with a market capitalisation of ₹61,576 crores, delivered a mixed performance in Q4 FY26 (January-March 2026), reporting a consolidated net profit of ₹301.41 crores. Whilst the company demonstrated robust year-on-year growth of 6,381.94% from an exceptionally low base in Q4 FY25, the quarter witnessed a sequential decline of 25.25% from Q3 FY26's strong showing of ₹403.21 crores. The stock has reacted cautiously, trading at ₹2,184.90 as of June 2, 2026, down 0.74% from the previous close, reflecting investor concerns about the sequential moderation despite impressive annual comparisons.

Glenmark Pharmaceuticals Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a day decline of 3.21% to close at ₹2,201.20, the stock’s broader technical indicators reveal a complex interplay of signals that investors should carefully analyse.

Glenmark Pharmaceuticals Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. Despite a recent dip in share price, the company’s fundamental metrics and relative valuation against peers suggest a compelling investment case for mid-cap investors seeking exposure in the pharmaceutical space.

Rs 2,200 put options on Glenmark Pharmaceuticals Ltd. attracted significant attention on 1 June 2026, with 1,971 contracts traded against an underlying price of Rs 2,197.10. This strike sits marginally out-of-the-money, raising questions about whether the activity signals protective hedging or a directional bearish stance.

Glenmark Pharmaceuticals Ltd. is rated 'Strong Buy' by MarketsMOJO, with this rating last updated on 19 May 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the company’s current position as of 31 May 2026, providing investors with the most up-to-date insight into the stock’s performance and outlook.

Glenmark Pharmaceuticals Ltd. has demonstrated a notable shift in technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by strong signals from key technical indicators such as the MACD, moving averages, and Bollinger Bands, suggesting a positive outlook for the mid-cap pharmaceutical player amid a volatile market backdrop.

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, reflecting heightened investor interest and a possible directional shift in market sentiment. The pharmaceutical mid-cap stock outperformed its sector and broader indices, supported by robust volume and delivery trends, signalling renewed confidence among traders and investors alike.

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, reflecting heightened market activity and a potential shift in investor sentiment. The stock outperformed its sector peers with a 3.24% gain on 25 May 2026, supported by a 15.55% increase in open interest, signalling robust bullish positioning among traders.

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, reflecting heightened investor interest and a possible shift in market sentiment. The stock outperformed its sector and broader indices, supported by robust volume and rising delivery volumes, signalling strong bullish positioning among traders and investors alike.

Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased market participation and potential directional bets. The stock outperformed its sector peers with a 4.15% gain on 25 May 2026, supported by rising volumes and a strong mojo score upgrade to 81.0, reflecting robust investor confidence in this mid-cap pharmaceutical player.

Glenmark Pharmaceuticals Ltd. witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a volatile trading session marked by a 5.09% decline in the stock price, the pharmaceutical mid-cap’s derivatives market displayed robust volume and increased open interest, suggesting strategic directional bets by traders.

Glenmark Pharmaceuticals Ltd. witnessed a significant surge in open interest in its derivatives segment on 22 May 2026, signalling heightened market activity and shifting investor positioning. Despite a sharp intraday decline of 5.45%, the stock’s derivatives market saw a 23.4% increase in open interest, reflecting a complex interplay of directional bets amid volatile trading conditions.

Glenmark Pharmaceuticals Ltd. witnessed a significant 15.04% rise in open interest in its derivatives segment on 22 May 2026, signalling heightened market activity despite the stock underperforming its sector and broader indices. This surge in open interest, coupled with volume patterns and price movements, offers insights into evolving market positioning and potential directional bets among traders.